The Future of Non-Animal Research Methods in Europe: A €1 Billion Opportunity
The European Union is at a pivotal juncture with a proposed investment of €1 billion in a Non-Animal Methods (NAMs) Moonshot Programme as part of Horizon Europe from 2028 to 2034. This initiative aims to significantly enhance the development, validation, and implementation of research methods that are more relevant to human health across all stages of innovation—from early discovery phases through to final deployment.
Current Investment Landscape
As it stands, Europe’s investment strategy in life sciences is falling short. The recent plan, titled “Choose Europe for Life Sciences,” promises an annual budget of €10 billion through various EU funding initiatives to fortify Europe’s position as a global leader in health and life sciences. However, only €50 million has been allocated for NAMs between 2026 and 2027, a figure that clearly lacks the necessary heft to bolster EU innovation or reinforce its competitive edge.
Global Context and Comparisons
In contrast, other countries have recognized the immense potential of NAMs and are backing their development with substantial investments. The United States initiated the NIH Complement-ARIE program in 2024, which boasts a budget of $400 million over ten years to propel non-animal research approaches forward. Meanwhile, the Netherlands has invested €245 million into the Utrecht Ombion Centre for Animal-Free Biomedical Translation in 2025. Clearly, the current €50 million earmarked by the EU is inadequate to meet the challenges ahead.
A Bold Proposal: The NAMs Moonshot Programme
With Horizon Europe anticipated to double its budget and highlight ambitious moonshot projects, the EU has a critical opportunity to significantly increase funding for NAMs, positioning itself as a frontrunner in cutting-edge, human-centric life sciences. The proposed €1 billion Nam Moonshot Programme aligns well with the goals of the European Research Area, focusing on key areas such as validation, infrastructure support, educational initiatives, and public awareness.
Essential Components for Success
To ensure the NAMs Moonshot succeeds, it is crucial to prioritize validation capacities that confirm NAMs operate reliably and effectively for their intended applications. Establishing robust infrastructure and providing comprehensive training will help build credibility and scalability in these scientific areas. Furthermore, education and public awareness are vital to develop a proficient workforce and promote the sustainable adoption of these innovative strategies, ultimately driving scientific progress and enhancing the EU’s competitiveness.
Integrating NAMs into Education
Incorporating NAMs and human-centered experimental design into educational curricula across various disciplines is essential. By embracing inter- and transdisciplinary learning that integrates advanced in vitro models, in silico tools, and artificial intelligence, we can equip future scientists with the necessary knowledge and skills to usher in this pivotal scientific transformation.
Conclusion
The proposed €1 billion investment in a NAMs Moonshot Programme represents a vital step towards advancing research methodologies that focus on human health while aligning with global trends. By fostering innovation and securing leadership in this domain, Europe can solidify its position in the future of life sciences.
Key Takeaways
- The EU is proposing a €1 billion NAMs Moonshot Programme for 2028-2034 to enhance human-relevant research methods.
- Current EU funding for NAMs is insufficient compared to investments made by countries like the U.S. and the Netherlands.
- Establishing robust validation, training, and education infrastructures will be crucial for the success of NAMs.
- Integrating NAMs into educational curricula is vital to prepare future researchers and drive scientific innovation.